Journal of Peking University(Health Sciences) >
Clinical characteristics and risk factors of cardiovascular disease in patients with elderly-onset rheumatoid arthritis: A large cross-sectional clinical study
Received date: 2020-07-10
Online published: 2020-12-13
Supported by
National Natural Science Foundation of China(81701598);National Natural Science Foundation of China(81801618);Beijing Natural Science Foundation(7192211)
Objective: To investigate the clinical characteristics of patients with elderly-onset rheumatoid arthritis (EORA), and the risk factors of EORA complicated with cardiovascular disease (CVD). Methods: A cross-sectional study was conducted in Peking University People’s Hospital from July 2009 to December 2014 and 1 116 patients were recruited. The patients’ characteristics and CVD, including ischemic heart disease, cerebral and peripheral vascular disease, were recorded. The patients were divided into EORA group (n=212) and younger-onset rheumatoid arthritis (YORA) group (n=904) according to the age of onset ≥60 years and <60 years. Then, the differences between the groups were analyzed by Student’s t test, Mann-Whitney U test or χ2test, and risk influencing CVD were analyzed using Logistic regression. Results: There was no significant difference in the disease activity between the EORA and YORA groups. The proportion of male, pulmonary interstitial disease (ILD), and numbers of deformity joint count (DJC) were significantly higher in the EORA group compared with the YORA group [32.1% vs. 18.5%, χ2=19.11, P<0.001; 23.6% vs. 13.6%, χ2=16.50, P<0.001; 6 (2, 12) vs. 3 (2, 7), Z=-3.60, P<0.001], while the prevalence of Sj?gren’s syndrome was lower than that of the YORA group (13.5% vs. 5.2%, χ2=11.29, P=0.001). Moreover, there were lower prevalences in the patients treated with disease-modifying antirheumatic drugs (DMARDs) in EORA group (35.4%) than in YORA group (26.7%) (χ2=6.43, P=0.011), especially in methotrexate (MTX), hydroxychloroquine (HCQ) and sulfasalazine (SSZ). In addition, the patients with EORA had a higher prevalence of CVD (27.8%) than the YORA group (11.6%, χ2=40.46, P<0.001), accompanied with higher prevalence of smoking, hypertension, and hyperlipidemia. Multivariate Logistic regression analysis showed that elder age (OR=1.10, 95%CI: 1.00-1.20), DJC (OR=3.17, 95%CI: 1.04-9.68), rheumatoid nodules (OR=3.56, 95%CI: 1.03-12.23), hypertension (OR=2.37, 95%CI: 1.09-5.13) and hyperlipidemia (OR=8.85, 95%CI: 2.50-31.27) were independent risk factors, while HCQ (OR=0.22, 95%CI: 0.07-0.70) and MTX (OR=0.32, 95%CI: 0.14-0.73) were protective factors of EORA complicated with CVD. Conclusion: Compared with YORA, patients with EORA have higher ratio of male, ILD and DJC, which may be attributed to inappropriate therapies. EORA is more likely to be complicated with CVD than YORA. Elder age, DJC, rheumatoid nodules, hypertension, and hyperlipidemia are independent risk factors, while HCQ and MTX are protective factors of EORA complicated with CVD.
Key words: Rheumatoid arthritis; Aged; Cardiovascular diseases; Risk factors
Jia-li CHEN , Yue-bo JIN , Yi-fan WANG , Xiao-ying ZHANG , Jing LI , Hai-hong YAO , Jing HE , Chun LI . Clinical characteristics and risk factors of cardiovascular disease in patients with elderly-onset rheumatoid arthritis: A large cross-sectional clinical study[J]. Journal of Peking University(Health Sciences), 2020 , 52(6) : 1040 -1047 . DOI: 10.19723/j.issn.1671-167X.2020.06.009
| [1] | Serhal L, Lwin MN, Holroyd C, et al. Rheumatoid arthritis in the elderly: Characteristics and treatment considerations[J]. Autoimmun Rev, 2020,19(6):102528. |
| [2] | Boots AM, Maier AB, Stinissen P, et al. The influence of ageing on the development and management of rheumatoid arthritis[J]. Nat Rev Rheumatol, 2013,9(10):604-613. |
| [3] | Meune C, Touze E, Trinquart L, et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies[J]. Rheumatology (Oxford), 2009,48(10):1309-1313. |
| [4] | Nicola PJ, Crowson CS, Maradit-Kremers H, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis[J]. Arthritis Rheum, 2006,54(1):60-67. |
| [5] | Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2010,69(9):1580-1588. |
| [6] | Salaffi F, Cimmino MA, Leardini G, et al. Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI)[J]. Clin Exp Rheumatol, 2009,27(4):552-559. |
| [7] | Li C, Wang XR, Ji HJ, et al. Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China[J]. Clin Rheumatol, 2017,36(5):1023-1029. |
| [8] | Tan TC, Gao X, Thong BY, et al. Comparison of elderly- and young-onset rheumatoid arthritis in an Asian cohort[J]. Int J Rheum Dis, 2017,20(6):737-745. |
| [9] | Spinel-Bejarano N, Quintana G, Heredia R, et al. Comparative study of elderly-onset rheumatoid arthritis and young-onset rheumatoid arthritis in a Colombian population: clinical, laboratory and HLA-DRB1 findings[J]. Clin Exp Rheumatol, 2013,31(1):40-46. |
| [10] | Cho SK, Sung YK, Choi CB, et al. Do patients with elderly-onset rheumatoid arthritis have severe functional disability?[J]. Semin Arthritis Rheum, 2012,42(1):23-31. |
| [11] | Dejaco C, Duftner C, Wipfler-Freissmuth E, et al. Elderly- versus younger-onset rheumatoid arthritis: higher levels of ultrasound-detected inflammation despite comparable clinical disease activity[J]. Arthritis Care Res (Hoboken), 2013,65(2):304-308. |
| [12] | Nielsen SF, Bojesen SE, Schnohr P, et al. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study[J]. BMJ, 2012,345:e5244. |
| [13] | Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica[J]. Rheumatology (Oxford), 2004,43(5):655-657. |
| [14] | van Schaardenburg D, Lagaay AM, Otten HG, et al. The relation between class-specific serum rheumatoid factors and age in the general population[J]. Br J Rheumatol, 1993,32(7):546-549. |
| [15] | Panoulas VF, Douglas KMJ, Milionis HJ, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis[J]. Rheumatology, 2007,46(9):1477-1482. |
| [16] | Erum U, Ahsan T, Khowaja D. Lipid abnormalities in patients with rheumatoid arthritis[J]. Pak J Med Sci, 2017,33(1):227-230. |
| [17] | Arnold N, Koenig W. Atherosclerosis as an inflammatory disease—pathophysiology, clinical relevance and therapeutic implications[J]. Dtsch Med Wochenschr, 2019,144(5):315-321. |
| [18] | Chen DY, Hsieh TY, Chen YM, et al. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease[J]. Gerontology, 2009,55(3):250-258. |
| [19] | Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis[J]. Ann Rheum Dis, 2015,74(3):480-489. |
| [20] | Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients[J]. Arthritis Care Res (Hoboken), 2011,63(4):530-534. |
| [21] | Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus[J]. J Rheumatol, 2010,37(6):1136-1142. |
| [22] | Widdifield J, Abrahamowicz M, Paterson JM, et al. Associations between methotrexate use and the risk of cardiovascular events in patients with elderly-onset rheumatoid arthritis[J]. J Rheumatol, 2019,465(5):467-474. |
| [23] | Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research[J]. Ann Rheum Dis, 2009,68(7):1100-1104. |
| [24] | Baghdadi LR, Woodman RJ, Shanahan EM, et al. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis[J]. PLoS One, 2015,10(2):e0117952. |
/
| 〈 |
|
〉 |